N. André, A. Rome, C. Coze, L. Padovani, E. Pasquier et al., Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: A preliminary monocentric study, Clinical Therapeutics, vol.30, issue.7, pp.30-1336, 2008.
DOI : 10.1016/S0149-2918(08)80059-8

D. Barbolosi, A. Benabdallah, F. Hubert, and F. Verga, Mathematical and numerical analysis for a model of growing metastatic tumors, Mathematical Biosciences, vol.218, issue.1, pp.1-14, 2009.
DOI : 10.1016/j.mbs.2008.11.008
URL : https://hal.archives-ouvertes.fr/hal-00262335

D. Barbolosi, G. Freyer, J. Ciccolini, and A. Iliadis, Optimisation de la posologie et des modalités d'administration des agents cytotoxiquesàcytotoxiques`cytotoxiquesà l'aide d'un modèle mathématique, Bulletin du Cancer, issue.2, pp.90-167, 2003.

D. Barbolosi and A. Iliadis, Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK???PD model, Computers in Biology and Medicine, vol.31, issue.3, pp.31-157, 2001.
DOI : 10.1016/S0010-4825(00)00032-9

D. Barbolosi, F. Verga, A. Benabdallah, F. Hubert, C. Mercier et al., Modélisation du rique d'´ evolution métastatique chez les patients supposés avoir une maladie localisée, Oncologie, issue.8, pp.13-528, 2011.
DOI : 10.1007/s10269-011-2028-6
URL : https://hal.archives-ouvertes.fr/hal-00549880/document

S. Baruchel, M. Diezi, D. Hargrave, D. Stempak, J. Gammon et al., Safety and pharmacokinetics of temozolomide using a doseescalation , metronomic schedule in recurrent paediatric brain tumours, Eur. J. Cancer, pp.42-2335, 2006.

S. Benzekry, Mathematical analysis of a two-dimensional population model of metastatic growth including angiogenesis, J. Evol. Equ, vol.11, issue.1, p.187, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00516693

S. Benzekry, Mathematical and numerical analysis of a model for anti-angiogenic therapy in metastatic cancers, ESAIM: Mathematical Modelling and Numerical Analysis, vol.46, issue.2, pp.207-237, 2012.
DOI : 10.1051/m2an/2011041
URL : https://hal.archives-ouvertes.fr/hal-00518110

S. Benzekry, Passing to the limit 2D???1D in a model for metastatic growth, Journal of Biological Dynamics, vol.59, issue.sup1, 2011.
DOI : 10.1016/0025-5564(90)90021-P
URL : https://hal.archives-ouvertes.fr/hal-00521968

S. Benzekry and A. Benabdallah, An optimal control problem for anti-cancer therapies in a model for metastatic evolution, 2011.

S. Benzekry, G. Chapuisat, J. Ciccolini, A. Erlinger, and H. F. , A new mathematical model for optimizing the combination between anti-angiogenic and cytotoxic drugs in oncology, 2011.

T. Browder, C. E. Butterfield, B. M. Kraling, B. Shi, B. Marshall et al., Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer, Cancer Res, pp.60-1878, 2000.

R. Bruno, N. Vivier, J. C. Vergniol, S. L. De-phillips, G. Montay et al., A population pharmacokinetic model for docetaxel (Taxotere??): Model building and validation, Journal of Pharmacokinetics and Biopharmaceutics, vol.14, issue.2
DOI : 10.1007/BF02353487

M. Casanova, A. Ferrari, G. Bisogno, J. H. Merks, G. L. De-salvo et al., Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas, Cancer, vol.11, issue.7, pp.101-1664, 2004.
DOI : 10.1002/cncr.20544

M. Chefrour, J. L. Fischel, P. Formento, S. Giacometti, R. M. Ferri-dessens et al., Erlotinib in Combination with Capecitabine (5'dFUR) in Resistant Pancreatic Cancer Cell Lines, Journal of Chemotherapy, vol.26, issue.5, pp.22-129, 2010.
DOI : 10.1038/sj.onc.1207769

L. M. Choi, B. Rood, N. Kamani, D. La-fond, R. J. Packer et al., Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors, Pediatric Blood & Cancer, vol.81, issue.5, pp.50-970, 2008.
DOI : 10.1002/pbc.21381

E. Comen, L. Norton, and J. Massague, Clinical implications of cancer self-seeding, Nature Reviews Clinical Oncology, vol.18, pp.369-377, 2011.
DOI : 10.1038/nrclinonc.2011.64

A. Devys, T. Goudon, and P. Laffitte, A model describing the growth and the size distribution of multiple metastatic tumors, Discrete and Continuous Dynamical Systems - Series B, vol.12, issue.4, 2009.
DOI : 10.3934/dcdsb.2009.12.731
URL : https://hal.archives-ouvertes.fr/inria-00351489

A. Onofrio, A. Gandolfi, and A. Rocca, The dynamics of tumour-vasculature interaction suggests low-dose, time-dense anti-angiogenic schedulings, Cell Prolif, pp.42-317, 2009.

J. M. Ebos, C. R. Lee, W. Crus-munoz, G. A. Bjarnason, and J. G. Christensen, Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis, Cancer Cell, vol.15, issue.3, pp.15-232, 2009.
DOI : 10.1016/j.ccr.2009.01.021

J. Folkman, Anti-Angiogenesis, Annals of Surgery, vol.175, issue.3, pp.409-416, 1972.
DOI : 10.1097/00000658-197203000-00014

A. Fontana, A. Falcone, L. Derosa, T. Di-desidero, R. Danesi et al., Metronomic Chemotherapy for Metastatic Prostate Cancer, Drugs & Aging, vol.56, issue.5, pp.27-689, 2010.
DOI : 10.2165/11537480-000000000-00000

A. B. Francesconi, S. Dupre, M. Matos, D. Martin, B. G. Hughes et al., Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme, Journal of Clinical Neuroscience, vol.17, issue.8, pp.17-970, 2010.
DOI : 10.1016/j.jocn.2009.12.009

G. Gasparini, R. Longo, M. Fanelli, and B. A. Teicher, Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions, Journal of Clinical Oncology, vol.23, issue.6, pp.1295-1311, 2005.
DOI : 10.1200/JCO.2005.10.022

P. Hahnfeldt, J. Folkman, and L. Hlatky, Minimizing Long-Term Tumor Burden: The Logic for Metronomic Chemotherapeutic Dosing and its Antiangiogenic Basis, Journal of Theoretical Biology, vol.220, issue.4, pp.545-554, 2003.
DOI : 10.1006/jtbi.2003.3162

P. Hahnfeldt, D. Panigraphy, J. Folkman, and L. Hlatky, Tumor development under angiogenic signaling : a dynamical theory of tumor growth, treatment, response and postvascular dormancy, Cancer Research, vol.59, pp.4770-4775, 1999.

A. Iliadis and D. Barbolosi, Optimizing Drug Regimens in Cancer Chemotherapy by an Efficacy???Toxicity Mathematical Model, Computers and Biomedical Research, vol.33, issue.3, pp.211-226, 2000.
DOI : 10.1006/cbmr.2000.1540

K. Iwata, K. Kawasaki, and N. Shigesada, A Dynamical Model for the Growth and Size Distribution of Multiple Metastatic Tumors, Journal of Theoretical Biology, vol.203, issue.2, pp.177-186, 2000.
DOI : 10.1006/jtbi.2000.1075

R. K. Jain, Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy, Nature Medicine, vol.7, issue.9, pp.987-989, 2001.
DOI : 10.1038/nm0901-987

K. Jordan, H. H. Wolf, W. Voigt, T. Kegel, L. P. Mueller et al., Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study, Bone Marrow Transplantation, vol.71, issue.12, pp.45-1704, 2010.
DOI : 10.1158/1078-0432.CCR-08-2170

R. S. Kerbel and B. A. Kamen, The anti-angiogenic basis of metronomic chemotherapy, Nature Reviews Cancer, vol.22, issue.6, pp.423-436, 2004.
DOI : 10.1200/JCO.2004.07.060

M. W. Kieran, C. D. Turner, J. B. Rubin, S. N. Chi, M. A. Zimmerman et al., A Feasibility Trial of Antiangiogenic (Metronomic) Chemotherapy in Pediatric Patients With Recurrent or Progressive Cancer, Journal of Pediatric Hematology/Oncology, vol.27, issue.11, pp.27-573, 2005.
DOI : 10.1097/01.mph.0000183863.10792.d4

S. Koscielny, M. Tubiana, M. G. Le, A. J. Valleron, H. Mouriesse et al., Breast cancer: Relationship between the size of the primary tumour and the probability of metastatic dissemination, British Journal of Cancer, vol.49, issue.6, pp.49-709, 1984.
DOI : 10.1038/bjc.1984.112

J. F. Lu, R. Bruno, S. Eppler, W. Novotny, B. Lum et al., Clinical pharmacokinetics of bevacizumab in patients with solid tumors, Cancer Chemotherapy and Pharmacology, vol.28, issue.5, pp.62-779, 2008.
DOI : 10.1007/s00280-007-0664-8

C. Meille, J. C. Gentet, D. Barbolosi, N. Andre, F. Doz et al., New Adaptive Method for Phase I Trials in Oncology, Clinical Pharmacology & Therapeutics, vol.15, issue.6, pp.873-881, 2008.
DOI : 10.1038/sj.clpt.6100383

C. Meille, A. Iliadis, D. Barbolosi, N. Frances, and G. Freyer, An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics, Journal of Pharmacokinetics and Pharmacodynamics, vol.63, issue.6, pp.619-633, 2008.
DOI : 10.1007/s10928-008-9106-4

M. Paez-ribes, E. Allen, J. Hudock, T. Takeda, H. Okuyama et al., Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis, Cancer Cell, vol.15, issue.3, pp.15-220, 2009.
DOI : 10.1016/j.ccr.2009.01.027

E. Pasquier, M. Kavallaris, and N. Andre, Metronomic chemotherapy: new rationale for new directions, Nature Reviews Clinical Oncology, vol.1805, issue.8, pp.455-465, 2010.
DOI : 10.1038/nrclinonc.2010.82

D. A. Reardon, A. Desjardins, K. Peters, S. Gururangan, J. Sampson et al., Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy, Journal of Neuro-Oncology, vol.12, issue.2, pp.371-379, 2011.
DOI : 10.1007/s11060-010-0403-6

A. R. Reynolds, Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer, Dose-Response, vol.74, issue.3, pp.253-284, 2010.
DOI : 10.1158/0008-5472.CAN-04-4409

J. R. Azzoli, F. M. Brahmer, V. E. Sirotnak, M. Seshan, M. Fogle et al., Randomized phase ii study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer, J. Clin. Oncol, issue.2, pp.27-264, 2009.

D. R. Spigel, P. M. Townley, D. M. Waterhouse, L. Fang, I. Adiguzel et al., Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial, Journal of Clinical Oncology, vol.29, issue.16, pp.29-2215, 2011.
DOI : 10.1200/JCO.2010.29.3423

D. Stempak, J. Gammon, J. Halton, A. Moghrabi, G. Koren et al., A Pilot Pharmacokinetic and Antiangiogenic Biomarker Study of Celecoxib and Low-dose Metronomic Vinblastine or Cyclophosphamide in Pediatric Recurrent Solid Tumors, Journal of Pediatric Hematology/Oncology, vol.28, issue.11, pp.28-720, 2006.
DOI : 10.1097/01.mph.0000243657.64056.c3

J. Sterba, D. Valik, P. Mudry, T. Kepak, Z. Pavelka et al., Combined Biodifferentiating and Antiangiogenic Oral Metronomic Therapy is Feasible and Effective in Relapsed Solid Tumors in Children: Single-Center Pilot Study, Oncology Research and Treatment, vol.29, issue.7, pp.29-308, 2006.
DOI : 10.1159/000093474

F. Verga, Modélisation mathématique de processus métastatiques, 2010.

P. Viens, H. Roche, P. Kerbrat, P. Fumoleau, J. P. Guastalla et al., Epirubicin-Docetaxel Combination in First-Line Chemotherapy for Patients With Metastatic Breast Cancer, American Journal of Clinical Oncology, vol.24, issue.4, pp.24-328, 2001.
DOI : 10.1097/00000421-200108000-00002